Company Overview - BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing and commercializing oral therapies for rare diseases, with its lead product targeting hereditary angioedema [2] - The oral therapy offers a convenient alternative to injectable treatments, enhancing patient preference for ease of use and consistent symptom control [2] Financial Metrics - As of March 16th, BCRX's share was trading at $9.30, with trailing and forward P/E ratios of 7.69 and 109.89 respectively [1] Growth Drivers - Revenue growth is supported by expanding global distribution and increasing physician awareness, alongside a pipeline targeting complement-mediated and other rare disorders, which offers potential long-term catalysts [3] - The company benefits from strong pricing power, regulatory incentives, and active patient advocacy within the rare disease biotech niche [3] Market Dynamics - Specialty pharmaceuticals like BCRX are less sensitive to traditional economic cycles, which supports the investment case [4] - Investor sentiment toward biotech has strengthened as capital markets stabilize, creating favorable conditions for share performance [4] Technical Analysis - Recent price action indicates renewed momentum, with a confirmation bar on increasing volume pushing the stock into a momentum zone where demand may accelerate as supply tightens [4] - Trailing stops anchored to Fibonacci retracement levels allow investors to protect gains while participating in potential upside [5] Investment Opportunity - BioCryst represents a compelling opportunity in rare disease biotechnology, combining a growing commercial franchise, an expanding pipeline, and supportive market dynamics [5] - The company offers both near-term growth from its hereditary angioedema therapy and longer-term upside through future pipeline developments [5]

Core Viewpoint - BioMarin Pharmaceutical Inc. is raising $850 million through the issuance of senior unsecured notes to finance its acquisition of Amicus Therapeutics, Inc. and related expenses [1][2][3] Financing Details - The company priced its offering of $850 million of 5.500% senior unsecured notes due in 2034 at an issue price of 100.000% [1] - BioMarin completed the syndication of a new $2 billion senior secured term loan "B" facility, in addition to an existing $800 million senior secured term loan "A" facility and a $600 million senior secured revolving credit facility [2] - The net proceeds from the notes offering, along with borrowings from the term facilities and cash on hand, will be used to fund the acquisition and related fees [3] Redemption and Guarantees - Gross proceeds from the notes will be held in an escrow account until the acquisition is completed; if not completed by December 19, 2026, the notes will be redeemed at 100% of the initial issue price plus accrued interest [4] - The notes will be jointly and severally guaranteed by certain subsidiaries of BioMarin, including Amicus and its subsidiaries after the acquisition [5] Covenants and Restrictions - The indenture governing the notes will include customary covenants that restrict BioMarin and its subsidiaries from incurring additional debt, paying dividends, and other specified actions [6] Company Overview - BioMarin is a global biotechnology company focused on rare diseases, with a strong track record of innovation and a robust pipeline of therapies [9][10]